The SARS-CoV-2 nucleocapsid protein is a major component of the viral replication processes, integral to viral particle assembly, and is a major diagnostic marker for infection and immune protection.
In a new paper (still under peer review), researchers from Colorado State University describe a newly developed and characterized mouse monoclonal antibodies against the SARS-CoV-2 nucleocapsid protein. The anti-nucleocapsid (anti-N) monoclonal antibodies were tested in ELISA, western blot, and immunofluorescence analyses.The variable regions from the heavy and light chains from five select clones were cloned and sequenced, and preliminary epitope mapping of the sequenced clones was performed.
Future studies can utilize these antibodies for studies determining nucleocapsid protein structure, intracellular interactions, diagnostic development, and potential therapeutics. The new anti-N reagents described here will be of significant value in the fight against COVID-19.